Equities analysts expect PRA Health Sciences Inc (NASDAQ:PRAH) to post $750.33 million in sales for the current quarter, Zacks reports. Six analysts have issued estimates for PRA Health Sciences’ earnings, with the lowest sales estimate coming in at $734.00 million and the highest estimate coming in at $762.18 million. PRA Health Sciences posted sales of $568.80 million during the same quarter last year, which would indicate a positive year over year growth rate of 31.9%. The company is expected to announce its next quarterly earnings results on Wednesday, February 20th.
According to Zacks, analysts expect that PRA Health Sciences will report full-year sales of $2.89 billion for the current year, with estimates ranging from $2.88 billion to $2.90 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $3.17 billion, with estimates ranging from $3.11 billion to $3.23 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow PRA Health Sciences.
PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business had revenue of $717.60 million during the quarter, compared to analysts’ expectations of $729.63 million. During the same quarter last year, the firm posted $0.88 earnings per share. The firm’s revenue was up 23.3% on a year-over-year basis.
A number of equities research analysts have commented on the company. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 8th. Evercore ISI assumed coverage on PRA Health Sciences in a research note on Thursday, October 4th. They issued an “inline” rating and a $120.00 price objective for the company. Robert W. Baird raised their price objective on PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th. SunTrust Banks raised their price objective on PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research note on Monday, November 5th. Finally, UBS Group assumed coverage on PRA Health Sciences in a research note on Tuesday, October 9th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $111.50.
Hedge funds have recently bought and sold shares of the company. Twin Tree Management LP bought a new position in shares of PRA Health Sciences in the second quarter valued at approximately $120,000. Price Capital Management Inc. bought a new position in shares of PRA Health Sciences in the third quarter valued at approximately $121,000. Mount Yale Investment Advisors LLC lifted its holdings in shares of PRA Health Sciences by 103.6% in the second quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 867 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of PRA Health Sciences by 930.9% in the third quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 1,629 shares in the last quarter. Finally, Bremer Trust National Association bought a new position in shares of PRA Health Sciences in the third quarter valued at approximately $205,000. Institutional investors own 97.42% of the company’s stock.
Shares of PRA Health Sciences stock opened at $103.07 on Friday. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. PRA Health Sciences has a 52 week low of $79.20 and a 52 week high of $121.98. The company has a market capitalization of $7.20 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 1.60 and a beta of 0.77.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.